Penicillin v
Penicillin Potassium, V-cillin (penicillin v) is a small molecule pharmaceutical. Penicillin v was first approved as V-cillin on 1982-01-01. It is used to treat bacillus anthracis, bacterial infections, diphtheria, gram-positive bacterial infections, and meningococcal meningitis amongst others in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| infections | D007239 |
| nervous system diseases | D009422 |
Trade Name
FDA
EMA
Penicillin potassium, Penicillin-vk (discontinued: Beepen-vk, Betapen-vk, Ledercillin, Pen-vee, Penapar-vk, Penicillin potassium, Pfizerpen, Uticillin, V-cillin, Veetids)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| buffered penicillin g potassium | ANDA | 2020-02-22 |
| penicillin g potassium | ANDA | 2024-06-28 |
| penicillin v potasium | ANDA | 2021-01-13 |
| penicillin v potassium | ANDA | 2024-10-24 |
| pfizerpen | ANDA | 2024-08-27 |
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
116 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Syphilis | D013587 | EFO_0007504 | A53.9 | 1 | 3 | 5 | 6 | 3 | 17 |
| Infections | D007239 | EFO_0000544 | — | 1 | 1 | 2 | 10 | 2 | 16 |
| Pneumonia | D011014 | EFO_0003106 | — | — | 1 | 4 | 2 | 2 | 8 |
| Pharyngitis | D010612 | — | R07.0 | 1 | — | 5 | 1 | 1 | 8 |
| Communicable diseases | D003141 | — | — | — | — | 1 | 5 | 1 | 7 |
| Tonsillitis | D014069 | HP_0011110 | J03 | — | — | 4 | 2 | 1 | 7 |
| Sepsis | D018805 | HP_0100806 | A41.9 | 1 | — | 2 | 1 | 2 | 6 |
| Hypersensitivity | D006967 | HP_0012393 | T78.40 | — | 1 | — | 2 | 2 | 5 |
| Hiv infections | D015658 | EFO_0000764 | B20 | — | 1 | 2 | 1 | 1 | 4 |
| Bacterial infections | D001424 | — | A49 | 1 | 1 | 1 | 1 | 1 | 4 |
Show 37 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neurosyphilis | D009494 | EFO_0007339 | A50.4 | — | — | 1 | — | 2 | 3 |
| Treponemal infections | D014211 | EFO_1001217 | — | — | — | 2 | — | — | 2 |
| Neonatal sepsis | D000071074 | HP_0040187 | — | — | — | 1 | — | 1 | 2 |
| Toxemia | D014115 | — | — | — | — | 1 | — | 1 | 2 |
| Tuberculosis | D014376 | EFO_0000774 | A15-A19 | — | 1 | 1 | — | — | 1 |
| Cytomegalovirus infections | D003586 | EFO_0001062 | B25 | — | 1 | 1 | — | — | 1 |
| Malnutrition | D044342 | EFO_0008572 | E40-E46 | — | — | 1 | — | — | 1 |
| Microbial drug resistance | D004352 | — | — | — | — | 1 | — | — | 1 |
| Severe acute malnutrition | D000067011 | — | — | — | — | 1 | — | — | 1 |
| Bacterial endocarditis | D004697 | EFO_1000830 | — | — | — | 1 | — | — | 1 |
Show 12 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Heart diseases | D006331 | EFO_0003777 | I51.9 | — | 2 | — | — | 2 | 4 |
| Rheumatic heart disease | D012214 | EFO_1001161 | I09.9 | — | 2 | — | — | 2 | 4 |
| Rheumatic diseases | D012216 | — | M79.0 | — | 2 | — | — | 1 | 3 |
| Urinary bladder neoplasms | D001749 | — | C67 | 2 | 1 | — | — | — | 3 |
| Non-muscle invasive bladder neoplasms | D000093284 | — | — | 2 | 1 | — | — | — | 3 |
| Psoriasis | D011565 | EFO_0000676 | L40 | — | 1 | — | — | 1 | 2 |
| Covid-19 | D000086382 | — | — | — | 1 | — | — | — | 1 |
| Congenital abnormalities | D000013 | EFO_0003915 | Q89.9 | — | 1 | — | — | — | 1 |
| Lymphangioma | D008202 | — | D18.1 | — | 1 | — | — | — | 1 |
| Lymphatic abnormalities | D044148 | — | — | — | 1 | — | — | — | 1 |
Show 2 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 4 | — | — | — | — | 4 |
| Streptococcal infections | D013290 | EFO_1001476 | — | 1 | — | — | — | 1 | 2 |
| Bone fractures | D050723 | EFO_0003931 | T14.8 | 1 | — | — | — | — | 1 |
| Jaw fractures | D007572 | — | — | 1 | — | — | — | — | 1 |
| Mandibular fractures | D008337 | — | S02.6 | 1 | — | — | — | — | 1 |
| Oxidative stress | D018384 | EFO_1001905 | — | 1 | — | — | — | — | 1 |
| Brain neoplasms | D001932 | EFO_0003833 | C71 | 1 | — | — | — | — | 1 |
| Glioblastoma | D005909 | EFO_0000515 | — | 1 | — | — | — | — | 1 |
| Astrocytoma | D001254 | EFO_0000271 | — | 1 | — | — | — | — | 1 |
| Streptococcus agalactiae | D013292 | NCBITaxon_1311 | — | 1 | — | — | — | — | 1 |
Show 1 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Peritonsillar abscess | D000039 | EFO_0007429 | J36 | — | — | — | — | 2 | 2 |
| Sickle cell anemia | D000755 | EFO_0000697 | D57 | — | — | — | — | 2 | 2 |
| Critical illness | D016638 | — | — | — | — | — | — | 1 | 1 |
| Hiv seropositivity | D006679 | — | — | — | — | — | — | 1 | 1 |
| Yin deficiency | D016710 | — | — | — | — | — | — | 1 | 1 |
| Hepatitis c | D006526 | — | B19.2 | — | — | — | — | 1 | 1 |
| Chronic hepatitis c | D019698 | EFO_0004220 | B18.2 | — | — | — | — | 1 | 1 |
| Hepatitis | D006505 | HP_0012115 | K75.9 | — | — | — | — | 1 | 1 |
| Hepatitis a | D006506 | EFO_0007305 | B15 | — | — | — | — | 1 | 1 |
| Appendicitis | D001064 | EFO_0007149 | K37 | — | — | — | — | 1 | 1 |
Show 19 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Penicillin v |
| INN | phenoxymethylpenicillin |
| Description | Phenoxymethylpenicillin is a penicillin compound having a 6beta-(phenoxyacetyl)amino side-chain. It is a penicillin allergen and a penicillin. It is a conjugate acid of a phenoxymethylpenicillin(1-). |
| Classification | Small molecule |
| Drug class | penicillins |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC1(C)S[C@@H]2[C@H](NC(=O)COc3ccccc3)C(=O)N2[C@H]1C(=O)O |
Identifiers
| PDB | — |
| CAS-ID | 87-08-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL615 |
| ChEBI ID | 27446 |
| PubChem CID | 6869 |
| DrugBank | DB00417 |
| UNII ID | Z61I075U2W (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 4,634 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
4,164 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use